Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial.

BACKGROUND Chronic plaque psoriasis is frequently associated with obesity. The effect of a hypoenergetic diet on psoriasis has not been investigated. OBJECTIVE The objective was to investigate whether moderate weight loss (ie, 5-10% of body weight) increases the therapeutic response to a low dose of cyclosporine in obese patients with moderate-to-severe chronic plaque psoriasis. DESIGN A 24-wk randomized, controlled, investigator-blinded clinical trial was conducted in 61 patients. The efficacy of 2.5 mg x kg(-1)d(-1) cyclosporine combined with a low-calorie diet (intervention group) was compared with cyclosporine alone (control group) in obese patients [body mass index (in kg/m(2)) > 30] with moderate-to-severe psoriasis. The primary endpoint was an improvement from baseline of >or=75% in the Psoriasis Area and Severity Index (PASI 75 response) at week 24. RESULTS At week 24, the mean (+/- SD) reduction in body weight was 7.0% +/- 3.5 in the intervention group and was 0.2% +/- 0.9 in the control group (P < 0.001). The PASI 75 response was achieved by 20 of 30 patients (66.7%) treated with cyclosporine plus a low-calorie diet and by 9 of 31 (29.0%) patients treated with cyclosporine alone (P < 0.001). Four patients (13.3%) from the intervention group and 14 (45.1%) from the control group withdrew prematurely from the study (P < 0.001). CONCLUSIONS Obese patients with moderate-to-severe psoriasis increase their response to low-dose cyclosporine if a calorie-controlled diet is included in the treatment regimen. Lifestyle modifications, including a low-calorie diet, may supplement the pharmacologic treatment of obese psoriasis patients. This trial was registered at clinicaltrials.gov as NCT00512187.

[1]  P. Venge,et al.  A fasting and vegetarian diet treatment trial on chronic inflammatory disorders. , 1983, Acta dermato-venereologica.

[2]  J. Bastard,et al.  Adipokines: the missing link between insulin resistance and obesity. , 2008, Diabetes & metabolism.

[3]  A. Rissanen,et al.  Weight loss larger than 10% is needed for general improvement of levels of circulating adiponectin and markers of inflammation in obese subjects: a 3-year weight loss study. , 2008, European journal of endocrinology.

[4]  R. Mensink,et al.  Weight loss, but not fish oil consumption, improves fasting and postprandial serum lipids, markers of endothelial function, and inflammatory signatures in moderately obese men. , 2007, The Journal of nutrition.

[5]  Tosca L. Zern,et al.  Weight Loss Favorably Modifies Anthropometrics and Reverses the Metabolic Syndrome in Premenopausal Women , 2005, Journal of the American College of Nutrition.

[6]  V. Ho,et al.  Intermittent short courses of cyclosporin (Neoral(R)) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomized study. The PISCES Study Group. , 1999, The British journal of dermatology.

[7]  L. Färber,et al.  Low-dose short-term cyclosporine versus etretinate in psoriasis: improvement of skin, nail, and joint involvement. , 1995, Journal of the American Academy of Dermatology.

[8]  B. Gersh.  Risk of Myocardial Infarction in Patients With Psoriasis , 2007 .

[9]  A. Finlay,et al.  Ciclosporin in psoriasis clinical practice: an international consensus statement , 2004, The British journal of dermatology.

[10]  T. Hayakawa,et al.  Effect of obesity on cyclosporine trough concentrations in psoriasis patients. , 1998, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[11]  L. Dubertret,et al.  Efficacy and safety of oral cyclosporin A (CyA; Sandimmun®) for long‐term treatment of chronic severe plaque psoriasis , 1994, The British journal of dermatology.

[12]  Sang Mi Ahn,et al.  Effect of weight loss on some serum cytokines in human obesity: increase in IL-10 after weight loss. , 2008, The Journal of nutritional biochemistry.

[13]  M. Haugen,et al.  Vegetarian diet for patients with rheumatoid arthritis — Status: Two years after introduction of the diet , 1994, Clinical Rheumatology.

[14]  M. Maniscalco,et al.  Weight loss and asthma control in severely obese asthmatic females. , 2008, Respiratory medicine.

[15]  J. Koo.  A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis. OLP302 Study Group. , 1998, The British journal of dermatology.

[16]  Parvez Hossain,et al.  Obesity and diabetes in the developing world--a growing challenge. , 2007, The New England journal of medicine.

[17]  Akira Nagano,et al.  Calorie restricted diet and urinary pentosidine in patients with rheumatoid arthritis. , 2004, Journal of physiological anthropology and applied human science.

[18]  O. Førre,et al.  Controlled trial of fasting and one-year vegetarian diet in rheumatoid arthritis , 1991, The Lancet.

[19]  M. Lebwohl,et al.  The effect of weight on the efficacy of biologic therapy in patients with psoriasis. , 2008, Journal of the American Academy of Dermatology.

[20]  B. Thiers.  Impact of Obesity and Smoking on Psoriasis Presentation and Management , 2006 .

[21]  T. Annesley,et al.  Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial. , 1991, The New England journal of medicine.

[22]  F. Granath,et al.  Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients , 2003, European Journal of Epidemiology.

[23]  Griffiths,et al.  Intermittent short courses of cyclosporin (Neoral®) for psoriasis unresponsive to topical therapy: a 1‐year multicentre, randomized study , 1999 .

[24]  G. Hotamisligil,et al.  Inflammation and metabolic disorders , 2006, Nature.

[25]  D. Beri,et al.  Effect of dietary restrictions on disease activity in rheumatoid arthritis. , 1988, Annals of the rheumatic diseases.

[26]  L. Färber,et al.  Low-dose (1.25 mg/kg) cyclosporin A: treatment of psoriasis and investigation of the influence on lipid profile. , 1997, Acta dermato-venereologica.

[27]  M. Weichenthal,et al.  Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis , 2006, Archives of Dermatological Research.

[28]  N. Schork,et al.  Alcohol intake and treatment responsiveness of psoriasis: a prospective study. , 1993, Journal of the American Academy of Dermatology.

[29]  M. Neves,et al.  Remission of Psoriasis after Open Gastric Bypass , 2006, Obesity surgery.

[30]  U. Mrowietz,et al.  Cyclosporine in psoriasis: a multicenter dose-finding study in severe plaque psoriasis. The German Multicenter Study. , 1992, Journal of the American Academy of Dermatology.

[31]  L. Niskanen,et al.  Effect of weight loss on cytokine messenger RNA expression in peripheral blood mononuclear cells of obese subjects with the metabolic syndrome. , 2008, Metabolism: clinical and experimental.

[32]  H. Yoon,et al.  A comparison of two cyclosporine dosage regimens for the treatment of severe psoriasis , 2007, The Journal of dermatological treatment.

[33]  B. Thiers.  Obesity, Waist Circumference, Weight Change, and the Risk of Psoriasis in Women: Nurses' Health Study II , 2008 .

[34]  A. Goldfine,et al.  Inflammation and insulin resistance. , 2006, The Journal of clinical investigation.

[35]  K. Schechtman,et al.  Improvements in glucose tolerance and insulin action induced by increasing energy expenditure or decreasing energy intake: a randomized controlled trial. , 2006, The American journal of clinical nutrition.

[36]  F. G. Benedict,et al.  A biometric study of basal metabolism in man , 2010 .

[37]  Samuel Szomstein,et al.  Psoriasis Remission after Laparoscopic Roux-En-Y Gastric Bypass for Morbid Obesity , 2004, Obesity surgery.

[38]  B. Nicklas,et al.  Inflammatory Biomarkers and Physical Function in Older, Obese Adults with Knee Pain and Self‐Reported Osteoarthritis After Intensive Weight‐Loss Therapy , 2008, Journal of the American Geriatrics Society.

[39]  J. Koo,et al.  A randomized, double‐blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis , 1998, The British journal of dermatology.

[40]  R. Kaufmann,et al.  Body-Weight-Independent Dosing of Cyclosporine Micro-Emulsion and Three Times Weekly Maintenance Regimen in Severe Psoriasis , 2002, Dermatology.

[41]  Hyon K. Choi,et al.  Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' Health Study II. , 2007, Archives of internal medicine.

[42]  B. Strober,et al.  Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review , 2007, The British journal of dermatology.

[43]  S. Piaserico,et al.  Prevalence of metabolic syndrome in patients with psoriasis: a hospital‐based case–control study , 2007, The British journal of dermatology.

[44]  L. Naldi,et al.  Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. , 2005, The Journal of investigative dermatology.

[45]  T. Reunala,et al.  Alcohol intake: a risk factor for psoriasis in young and middle aged men? , 1990, BMJ.

[46]  Daniel B. Shin,et al.  Prevalence of cardiovascular risk factors in patients with psoriasis. , 2006, Journal of the American Academy of Dermatology.

[47]  Corby K. Martin,et al.  Effect of 6-month calorie restriction on biomarkers of longevity, metabolic adaptation, and oxidative stress in overweight individuals: a randomized controlled trial. , 2006, JAMA.

[48]  P. Bossuyt,et al.  Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. , 2003, The New England journal of medicine.